Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes
Authors:
Open Access
- 22 May 2024
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 129, 102770
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82,272,865)
This publication has 71 references indexed in Scilit:
- 209P Efficacy and feasibility of long acting every three months goserelin for premenopausal breast cancer patients during COVID pandemicAnnals of Oncology, 2022
- ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)Annals of Oncology, 2022
- Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in ChinaJAMA Oncology, 2021
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021Annals of Oncology, 2021
- Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression TherapyThe Oncologist, 2021
- Sexual health and rehabilitation after ovarian suppression treatment (SHARE-OS): a clinical intervention for young breast cancer survivorsJournal of Cancer Survivorship, 2019
- Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative studyBreast Cancer, 2016
- Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free SurvivalJAMA, 2015
- Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancerBreast Cancer, 2015
- Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancerBreast Cancer Research and Treatment, 2011